The first assessment of soluble CD146 in women with unexplained pregnancy loss

Summary

The mechanisms responsible for pregnancy loss have not all been elucidated. CD146 is a cell adhesion molecule involved in the control of both endothelium integrity and intermediate trophoblast invasiveness, two potential key features in the pathogenesis of pregnancy loss. As CD146 is detectable as a soluble form in the plasma (sCD146), we investigated sCD146 plasma levels in women with a history of pregnancy loss. We conducted a paired case-control study to compare sCD146 plasma levels in 100 women with unexplained pregnancy losses (2 or more consecutive losses at or before 21 weeks of gestation, or at least one later loss) and in 100 age-matched control women (no pregnancy loss and at least one living child). The sCD146 concentrations were determined at least 2 months after the last obstetrical event. Patients and controls were comparable regarding thrombophilia. Among the patients, 83 women experienced early pregnancy losses (average of 3 losses, mean gestation of 6.6 weeks) and 22 women suffered at least one late pregnancy loss. We found significantly higher sCD146 plasma levels in the 100 patients compared to age matched control women (p<0.001). The sCD146 plasma levels did not correlate with the number of pregnancy losses nor with the mean gestation time. Alterations in sCD146 plasma levels could be related to endothelial dysfunction associated to defective endovascular trophoblast invasiveness. Additional studies should explore whether sCD146 assessment could provide diagnostic and prognostic information with a view to screening and thus managing women with unexplained pregnancy loss.

Keywords

Clinical / epidemiological studies - Adhesion molecules - CD146 - endothelial cells - pregnancy loss

• References

• 1 Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999; 14: 2868-71.
• 2 Stirrat GM. Recurrent miscarriage. II: Clinical associations, causes, and management. Lancet 1990; 336: 728-33.
• 3 Quenby SM, Farquharson RG. Predicting recurring miscarriage: what is important?. Obstet Gynecol 1993; 82: 132-8.
• 4 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
• 5 Laskin CA, Bombardier C, Hannah ME. et al Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-53.
• 6 Rai R, Cohen H, Dave M. et al Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
• 7 Grandone E, Margaglione M, Colaizzo D. et al Presence of FV Leiden and MTHFR mutation in a patient with complicated pregnancies. Thromb Haemost 1997; 77: 1036-7.
• 8 Balasch J, Reverter JC, Fabregues F. et al First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 1094-7.
• 9 Dizon-Townson DS, Kinney S, Branch DW. et al The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217-23.
• 10 Lindqvist PG, Svensson PJ, Marsaal K. et al Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
• 11 Gris JC, Quere I, Monpeyroux F. et al Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent– the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost 1999; 81: 891-9.
• 12 Fatini C, Gensini F, Battaglini B. et al Angiotensinconverting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000; 11: 657-62.
• 13 Foka ZJ, Lambropoulos AF, Saravelos H. et al Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15: 458-62.
• 14 Martinelli I, Taioli E, Cetin I. et al Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-8.
• 15 Meinardi JR, Middeldorp S, de Kam PJ. et al The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 625-31.
• 16 Preston FE, Rosendaal FR, Walker ID. et al Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
• 17 Sanson BJ, Friederich PW, Simioni P. et al The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-8.
• 18 Rey E, Kahn SR, David M. et al Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
• 19 Laude I, Rongieres-Bertrand C, Boyer-Neumann C. et al Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85: 18-21.
• 20 Carp H, Dardik R, Lubetsky A. et al Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study. Hum Reprod 2004; 19: 191-5.
• 21 Kurman RJ. The morphology, biology, and pathology of intermediate trophoblast: a look back to the present. Hum Pathol 1991; 22: 847-55.
• 22 Khong TY, Sawyer IH, Heryet AR. An immunohistologic study of endothelialization of uteroplacental vessels in human pregnancy - evidence that endothelium is focally disrupted by trophoblast in preeclampsia. Am J Obstet Gynecol 1992; 167: 751-6.
• 23 De Wolf F, Wolf-Peeters C, Brosens I. Ultrastructure of the spiral arteries in the human placental bed at the end of normal pregnancy. Am J Obstet Gynecol 1973; 117: 833-48.
• 24 Pijnenborg R, Bland JM, Robertson WB. et al Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983; 4: 397-413.
• 25 Lyall F. Development of the utero-placental circulation: the role of carbon monoxide and nitric oxide in trophoblast invasion and spiral artery transformation. Microsc Res Tech 2003; 60: 402-11.
• 26 Norwitz E, Schust DJ, Schust DJF. et al Implantation and the survival of early pregnancy. N Engl J Med 2001; 345: 1400-8.
• 27 Bardin N, Frances V, Lesaule G. et al Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996; 218: 210-6.
• 28 Bardin N, Anfosso F, Masse JM. et al Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98: 3677-84.
• 29 Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999; 189: 4-11.
• 30 Kayisli UA, Luk J, Guzeloglu-Kayisli O. et al Regulation of angiogenic activity of human endometrial endothelial cells in culture by ovarian steroids. J Clin Endocrinol Metab 2004; 89: 5794-802.
• 31 Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1989; 86: 9891-5.
• 32 Luca M, Hunt B, Bucana CD. et al Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993; 3: 35-41.
• 33 Shih I, Wang T, Wu T. et al Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells. J Cell Sci 1998; 111: 2655-64.
• 34 Liu Q, Yan X, Li Y. et al Pre-eclampsia is associated with the failure of melanoma cell adhesion molecule (MCAM/CD146) expression by intermediate trophoblast. Lab Invest 2004; 84: 221-8.
• 35 Chan B, Sinha S, Cho D. et al Critical roles of CD146 in zebrafish vascular development. Dev Dyn 2005; 232: 232-44.
• 36 Bardin N, Moal V, Anfosso F. et al Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003; 90: 915-20.
• 37 Malyszko J, Malyszko JS, Brzosko S. et al Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004; 89: 4620-7.
• 38 Ouchi N, Kihara S, Arita Y. et al Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
• 39 Rajagopalan S, Somers EC, Brook RD. et al Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-83.